While the current practice of conventional ER/PR scoring in clinical routine is reproducible, and widely established as rationale for treatment with anti-estrogen treatments such as aromatase inhibitors [4,13,14], the underlying causes for heterogeneous staining results, potentially due to regulation of ER/PR in response to the tumor microenvironment, are poorly understood. The gene discussed is ESR1; the disease is neoplasm.